These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35449223)

  • 1. Inhibitory effect of concomitantly administered rabies immunoglobulins on the immunogenicity of commercial and candidate human rabies vaccines in hamsters.
    Bernard MC; Boudet F; Pineda-Peña AC; Guinet-Morlot F
    Sci Rep; 2022 Apr; 12(1):6570. PubMed ID: 35449223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Pichon S; Moureau A; Petit C; Kirstein JL; Sheldon E; Guinet-Morlot F; Minutello AM
    Vaccine; 2024 Apr; 42(10):2553-2559. PubMed ID: 38105138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Pineda-Peña AC; Jiang Q; Petit C; Korejwo-Peyramond J; Donazzolo Y; Latreille M; Homery MC; Babin V; Benamor S; Pichon S; Guinet-Morlot F; Minutello AM
    Clin Infect Dis; 2024 Jun; 78(6):1748-1756. PubMed ID: 38478634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.
    Pichon S; Guinet-Morlot F; Saleh J; Essink B; Pineda-Peña AC; Moureau A; Petit C; Minutello AM
    Hum Vaccin Immunother; 2023 Dec; 19(3):2275453. PubMed ID: 37921410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Houillon G
    Vaccine; 2019 Apr; 37(16):2268-2277. PubMed ID: 30890382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
    Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
    Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Pichon S; Moureau A; Petit C; Chu L; Essink B; Muse D; Saleh J; Guinet-Morlot F; Minutello AM
    Vaccine; 2022 Aug; 40(33):4780-4787. PubMed ID: 35778281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.
    Pichon S; Guinet-Morlot F; Minutello M; Donazzolo Y; Rouzier R; Chassard D; Fitoussi S; Hou V
    Vaccine; 2013 Apr; 31(18):2295-301. PubMed ID: 23510665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.
    Quiambao BP; Lim JG; Bosch Castells V; Augard C; Petit C; Bravo C; Delore V; Houillon G
    Vaccine; 2022 Aug; 40(36):5347-5355. PubMed ID: 35933278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group.
    Lang J; Simanjuntak GH; Soerjosembodo S; Koesharyono C
    Bull World Health Organ; 1998; 76(5):491-5. PubMed ID: 9868840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).
    Ashwathnarayana DH; Madhusudana SN; Sampath G; Sathpathy DM; Mankeshwar R; Ravish HH; Ullas PT; Behra TR; Sudarshan MK; Gangaboraiah ; Shamanna M
    Vaccine; 2009 Dec; 28(1):148-51. PubMed ID: 19818720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines.
    Quiambao BP; Lang J; Vital S; Montalban CG; Le Mener V; Wood SC; Miranda E
    Acta Trop; 2000 Feb; 75(1):39-52. PubMed ID: 10708006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Rasuli A; Houillon G
    Vaccine; 2020 May; 38(21):3740-3746. PubMed ID: 32280042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Quiambao B; Montalban C; Minutello AM; Guinet-Morlot F; Moureau A; Petit C; Pichon S
    Vaccine; 2022 Aug; 40(35):5170-5178. PubMed ID: 35906106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China.
    Hou Q; Liu S; Liu C; Wang X; Shi J; Chen Q; Lv X; Zhu Z; Wang C; Yin W
    Travel Med Infect Dis; 2024; 60():102735. PubMed ID: 38992484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].
    Hacibektaşoğlu A; Inal A; Eyigün C; Barut A; Türkay FA
    Mikrobiyol Bul; 1992 Jan; 26(1):26-36. PubMed ID: 1574019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine.
    Lang J; Attanath P; Quiambao B; Singhasivanon V; Chanthavanich P; Montalban C; Lutsch C; Pepin-Covatta S; Le Mener V; Miranda M; Sabchareon A
    Acta Trop; 1998 Jul; 70(3):317-33. PubMed ID: 9777717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination (PVRV) in Iranian Patients with Specific Medical Conditions.
    Rahimi P; Vahabpour R; Aghasadeghi MR; Sadat SM; Howaizi N; Mostafavi E; Eslamifar A; Fallahian V
    PLoS One; 2015; 10(10):e0139171. PubMed ID: 26440665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers.
    Kulkarni PS; Sapru A; D'costa PM; Pandit A; Madhusudana SN; Yajaman AB; Mangrule S; Gunale B; Bavdekar AR
    Vaccine; 2013 May; 31(24):2719-22. PubMed ID: 23583817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.